Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

SanMedica’s SeroVital-hgh could revolutionize both anti-aging and weight-loss industries

While the Obesity Society's prestigious 30th Annual Scientific Meeting is the venue for some of the most cutting-edge obesity research in the world, at this year's conference the main highlight wasn't weight loss, but was instead — believe it or not — anti-aging. Research presented by a group of highly renowned scientists revealed an oral compound that experts are predicting could completely revolutionize both the anti-aging and weight-loss industries.

20 Feb 2013

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.

19 Feb 2013

Protein-restricted diet supplemented with IGF-I may protect from Alzheimer's

Mice with many of the pathologies of Alzheimer's Disease showed fewer signs of the disease when given a protein-restricted diet supplemented with specific amino acids every other week for four months.

15 Feb 2013

Longer looks: DIY abortions and the law; Helping other parents reach out to mentally ill children; Human growth hormone and Big Pharma

McCormack knew that an abortion would cost $400 to $2,000, depending on how far along she was. ... She couldn't come up with that kind of money. So she called her older sister, who owned a computer, and asked her to order abortion pills for her on the Internet.

3 Jan 2013

Novo Nordisk launches HemaGo mobile app to help individuals with hemophilia

Novo Nordisk announced today the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact of hemophilia on life events.

From Novo Nordisk 28 Nov 2012

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Lymphopenia is when you lack the T cells of your immune system. T cells are very important for controlling infection. Probably the most known cause of lymphopenia is HIV.

23 Nov 2012

Medgenics’ EPODURE Biopump technology for EPO delivery receives U.S. patent

Medgenics, Inc., the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics' EPODURE Biopump technology for delivery of erythropoietin (EPO).

22 Nov 2012

Prader-Willi children may receive relief from sleep disorders after adenotonsillectomy

Children with Prader-Willi syndrome may receive relief from sleep disorders after undergoing an adenotonsillectomy, suggests a new study from Nationwide Children's Hospital published in the November print issue of the Archives of Otolaryngology-Head and Neck Surgery.

21 Nov 2012

FGF21 hormone markedly increases life span in mice

A study by UT Southwestern Medical Center researchers finds that a starvation hormone markedly extends life span in mice without the need for calorie restriction.

17 Oct 2012

Positive results from PROLOR's Rpeg preclinical toxicology study

PROLOR Biotech, Inc. today announced positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology.

17 Oct 2012

BMI concerns raised for childhood stem cell transplantation survivors

Childhood survivors of hematologic malignancies treated with allogeneic hematopoietic stem cell transplantation should undergo long-term monitoring of their body mass index and lean body mass, US researchers recommend.

3 Oct 2012

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.

27 Sep 2012

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

Antares Pharma, Inc. today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).

25 Sep 2012

EPO grants patent to Aeterna Zentaris’ AEZS-130 for diagnosis of growth hormone deficiency

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency in a human or animal subject.

25 Sep 2012

U.K. scientists develop new test to catch drugs-cheats in sport

Scientists from three UK universities have developed a new test to catch drugs-cheats in sport.

15 Sep 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Aeterna Zentaris Inc. today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.

28 Aug 2012

USPTO issues patent to Aeterna Zentaris’ AEZS-130 oral test for AGHD

Aeterna Zentaris Inc. today announced that the United States Patent and Trademark Office has granted a patent for the use of its oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency.

7 Aug 2012

Obesity in mothers affects growth of children

Pregnant women who are overweight or obese can encounter a host of health complications. The added weight also appears to affect how their children grow and develop, at least initially.